1. OP0006 Safety and efficacy of lenabasum (JBT-101) in diffuse cutaneous systemic sclerosis subjects treated for one year in an open-label extension of trial jbt101-ssc-001. (12th June 2018) Authors: Spiera, R.; Hummers, L.; Chung, L.; Frech, T.; Domsic, R.; Hsu, V.; Furst, D.E.; Gordon, J.; Mayes, M.; Simms, R.; Lee, E.; Dgetluck, N.; Constantine, S.; White, B. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0313 CORRELATION BETWEEN PROGRESSION OF SKIN FIBROSIS AND PROGRESSION OF INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH SSC-ILD: DATA FROM THE SENSCIS TRIAL. (2nd June 2020) Authors: Distler, O.; Highland, K.; Hoffmann-Vold, A. M.; Kowal-Bielecka, O.; Walker, U.; Del Galdo, F.; Vonk, M.; Hummers, L.; Erhardt, E.; Quaresma, M.; Alves, M.; Smith, V. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗